PharmGKB ID	Name	Source	Biomarker Flag	Testing Level	Has Dosing Info	Has Alternate Drug	Cancer Genome
PA166104782	Annotation of FDA Label for azathioprine and NUDT15,TPMT	FDA	On	Testing recommended			
PA166104783	Annotation of FDA Label for rasburicase and CYB5R1,CYB5R2,CYB5R3,CYB5R4	FDA	On	Informative PGx			
PA166104784	Annotation of FDA Label for diazepam and CYP2C19	FDA	On	Actionable PGx			
PA166104785	Annotation of FDA Label for erlotinib and EGFR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104786	Annotation of FDA Label for chloroquine and G6PD	FDA	On	Actionable PGx			
PA166104787	Annotation of FDA Label for cevimeline and CYP2D6	FDA	On	Actionable PGx			
PA166104775	Annotation of FDA Label for atorvastatin and LDLR	FDA	Off (Formerly On)	Informative PGx			
PA166104778	Annotation of FDA Label for brentuximab vedotin and ALK,TNFRSF8	FDA	On	Informative PGx			Cancer Genome
PA166104777	Annotation of FDA Label for clopidogrel and CYP2C19	FDA	On	Actionable PGx			
PA166104779	Annotation of EMA Label for indacaterol and ADRB2	EMA	Off (Never On)	Informative PGx			
PA166104780	Annotation of FDA Label for carbamazepine and HLA-B	FDA	On	Testing required		Alternate Drug	
PA166104781	Annotation of FDA Label for dasatinib and ABL1,BCR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104800	Annotation of FDA Label for indacaterol and UGT1A1	FDA	On	Informative PGx			
PA166104801	Annotation of FDA Label for peginterferon alfa-2b and IFNL3	FDA	On	Actionable PGx			
PA166104802	Annotation of FDA Label for capecitabine and DPYD	FDA	On	Actionable PGx			
PA166104803	Annotation of FDA Label for maraviroc and CCR5	FDA	Off (Formerly On)	Testing required			
PA166104788	Annotation of FDA Label for fluoxetine / olanzapine and CYP2D6	FDA	Off (Never On)	Actionable PGx			
PA166104789	Annotation of FDA Label for gefitinib and EGFR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104790	Annotation of FDA Label for imatinib and ABL1,BCR,FIP1L1,KIT,PDGFRA,PDGFRB	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104791	Annotation of FDA Label for lapatinib and ERBB2,ESR1,ESR2,PGR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166151878	Annotation of FDA Label for lapatinib and HLA-DQA1,HLA-DRB1	FDA	On	Actionable PGx			
PA166104792	Annotation of FDA Label for fulvestrant and ESR1,ESR2,PGR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104793	Annotation of FDA Label for risperidone and CYP2D6	FDA	On	Informative PGx			
PA166104795	Annotation of FDA Label for busulfan and ABL1,BCR	FDA	On	Actionable PGx			Cancer Genome
PA166104794	Annotation of FDA Label for sodium benzoate / sodium phenylacetate and ARG1,ASL,ASS1,CPS1,NAGS,OTC	FDA	Off (Formerly On)	Testing required			
PA166104796	Annotation of FDA Label for trastuzumab emtansine and ERBB2	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104797	Annotation of FDA Label for letrozole and ESR1,ESR2,PGR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104798	Annotation of FDA Label for propranolol and CYP2D6	FDA	On	Informative PGx			
PA166104799	Annotation of FDA Label for tramadol and CYP2D6	FDA	On	Actionable PGx		Alternate Drug	
PA166104804	Annotation of FDA Label for tositumomab and MS4A1	FDA	Off (Formerly On)	Informative PGx			Cancer Genome
PA166104805	Annotation of FDA Label for thioridazine and CYP2D6	FDA	On	Actionable PGx		Alternate Drug	
PA166104806	Annotation of FDA Label for tolterodine and CYP2D6	FDA	On	Actionable PGx			
PA166104807	Annotation of FDA Label for fluorouracil and DPYD	FDA	On	Actionable PGx		Alternate Drug	
PA166104814	Annotation of FDA Label for drospirenone / ethinyl estradiol and CYP2C19	FDA	On	Informative PGx			
PA166104815	Annotation of FDA Label for clozapine and CYP2D6	FDA	On	Actionable PGx			
PA166104816	Annotation of FDA Label for esomeprazole and CYP2C19	FDA	On	Actionable PGx			
PA166104808	Annotation of FDA Label for nelfinavir and CYP2C19,CYP3A	FDA	Off (Formerly On)	Informative PGx			
PA166104809	Annotation of FDA Label for panitumumab and EGFR,KRAS,NRAS	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104811	Annotation of FDA Label for quinidine and CYP2D6	FDA	On	Informative PGx			
PA166104810	Annotation of FDA Label for mercaptopurine and NUDT15,TPMT	FDA	On	Testing recommended	Dosing Info		
PA166104812	Annotation of FDA Label for protriptyline and CYP2D6	FDA	On	Actionable PGx			
PA166104813	Annotation of FDA Label for carvedilol and CYP2D6	FDA	On	Actionable PGx			
PA166104825	Annotation of FDA Label for valproic acid and OTC	FDA	On	Actionable PGx		Alternate Drug	
PA166104826	Annotation of FDA Label for cetuximab and EGFR,KRAS,NRAS	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104827	Annotation of FDA Label for atomoxetine and CYP2D6	FDA	On	Actionable PGx	Dosing Info		
PA166104817	Annotation of FDA Label for tretinoin and PML,RARA	FDA	On	Testing required			Cancer Genome
PA166104818	Annotation of FDA Label for voriconazole and CYP2C19	FDA	On	Actionable PGx			
PA166104819	Annotation of FDA Label for tamoxifen and ESR1,ESR2,PGR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104820	Annotation of FDA Label for doxepin and CYP2C19,CYP2D6	FDA	On	Actionable PGx			
PA166104821	Annotation of EMA Label for arsenic trioxide and PML,RARA	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166104822	Annotation of FDA Label for terbinafine and CYP2D6	FDA	Off (Formerly On)	Informative PGx			
PA166104823	Annotation of EMA Label for methylene blue and BLVRB,CYB5R3,G6PD	EMA	Off (Never On)	Actionable PGx		Alternate Drug	
PA166104828	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2	FDA	Off (Formerly On)	Informative PGx			
PA166104829	Annotation of FDA Label for tetrabenazine and CYP2D6	FDA	On	Testing required	Dosing Info		
PA166104830	Annotation of FDA Label for tiotropium and CYP2D6	FDA	Off (Formerly On)	Informative PGx			
PA166104831	Annotation of FDA Label for irinotecan and UGT1A1	FDA	On	Actionable PGx	Dosing Info		
PA166104832	Annotation of FDA Label for carisoprodol and CYP2C19	FDA	On	Actionable PGx			
PA166104833	Annotation of FDA Label for abacavir and HLA-B	FDA	On	Testing required		Alternate Drug	
PA166104834	Annotation of FDA Label for lenalidomide	FDA	On	Testing required			
PA166104835	Annotation of FDA Label for fluoxetine and CYP2D6	FDA	On	Informative PGx			
PA166104836	Annotation of FDA Label for metoprolol and CYP2D6	FDA	On	Informative PGx			
PA166104837	Annotation of FDA Label for propafenone and CYP2D6	FDA	On	Actionable PGx			
PA166104838	Annotation of FDA Label for thioguanine and NUDT15,TPMT	FDA	On	Testing recommended	Dosing Info		
PA166104843	Annotation of FDA Label for celecoxib and CYP2C9	FDA	On	Actionable PGx	Dosing Info		
PA166104844	Annotation of EMA Label for erlotinib and EGFR	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166104845	Annotation of FDA Label for dapsone and G6PD	FDA	On	Actionable PGx			
PA166104846	Annotation of FDA Label for arsenic trioxide and PML,RARA	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104847	Annotation of FDA Label for venlafaxine and CYP2D6	FDA	On	Actionable PGx			
PA166104848	Annotation of FDA Label for rabeprazole and CYP2C19	FDA	On	Actionable PGx			
PA166104839	Annotation of FDA Label for aripiprazole and CYP2D6	FDA	On	Actionable PGx	Dosing Info		
PA166104840	Annotation of EMA Label for lapatinib and ERBB2,ESR1,ESR2	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166104841	Annotation of EMA Label for clopidogrel and CYP2C19	EMA	Off (Never On)	Actionable PGx			
PA166104842	Annotation of FDA Label for nilotinib and ABL1,BCR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166151974	Annotation of HCSC Label for nilotinib and UGT1A1	HCSC		Actionable PGx			
PA166159963	Annotation of FDA Label for blinatumomab and ABL1,BCR	FDA	On	Informative PGx			Cancer Genome
PA166160010	Annotation of FDA Label for dolutegravir and UGT1A1	FDA	On	Actionable PGx			
PA166160039	Annotation of FDA Label for evolocumab and LDLR	FDA	Off (Formerly On)	Informative PGx			
PA166160040	Annotation of FDA Label for Parathyroid Hormones And Analogues and CASR	FDA	On	Informative PGx			
PA166160049	Annotation of FDA Label for lacosamide and CYP2C19	FDA	On	Informative PGx			
PA166160051	Annotation of FDA Label for alectinib and ALK	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166160289	Annotation of HCSC Label for brivaracetam and CYP2C19	HCSC		Actionable PGx			
PA166160133	Annotation of FDA Label for palbociclib and ERBB2,ESR1,ESR2	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166160052	Annotation of FDA Label for palonosetron and CYP2D6	FDA	On	Informative PGx			
PA166104850	Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2	FDA	On	Informative PGx			
PA166104851	Annotation of FDA Label for ticagrelor and CYP2C19	FDA	On	Informative PGx			
PA166104852	Annotation of FDA Label for citalopram and CYP2C19,CYP2D6	FDA	On	Actionable PGx	Dosing Info		
PA166104853	Annotation of FDA Label for cisplatin and TPMT	FDA	On	Informative PGx			
PA166105213	Annotation of FDA Label for oxcarbazepine and HLA-B	FDA	On	Testing recommended		Alternate Drug	
PA166104854	Annotation of FDA Label for fluvoxamine and CYP2D6	FDA	On	Actionable PGx			
PA166104855	Annotation of FDA Label for boceprevir and IFNL3	FDA	On	Informative PGx			
PA166104858	Annotation of FDA Label for vemurafenib and BRAF	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104856	Annotation of FDA Label for amitriptyline and CYP2D6	FDA	On	Actionable PGx			
PA166104857	Annotation of FDA Label for trimipramine and CYP2D6	FDA	On	Actionable PGx			
PA166104859	Annotation of FDA Label for crizotinib and ALK,ROS1	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104860	Annotation of FDA Label for phenytoin and CYP2C19,CYP2C9,HLA-B	FDA	On	Actionable PGx			
PA166104872	Annotation of EMA Label for boceprevir and IFNL3	EMA	Off (Never On)	Actionable PGx			
PA166104874	Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD,NAT2	FDA	On	Actionable PGx			
PA166104875	Annotation of FDA Label for clomipramine and CYP2D6	FDA	On	Actionable PGx			
PA166104876	Annotation of FDA Label for primaquine and G6PD	FDA	On	Testing required		Alternate Drug	
PA166183184	Annotation of EMA Label for lorlatinib and ALK	EMA		Testing required		Alternate Drug	Cancer Genome
PA166169882	Annotation of FDA Label for deutetrabenazine and CYP2D6	FDA	On	Actionable PGx	Dosing Info		
PA166178724	Annotation of FDA Label for neratinib and ESR1,ESR2,PGR	FDA	On	Informative PGx			
PA166182742	Annotation of FDA Label for talazoparib and BRCA1,BRCA2	FDA	On	Testing required		Alternate Drug	
PA166182755	Annotation of FDA Label for vincristine and ABL1,BCR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166182728	Annotation of FDA Label for ropivacaine and G6PD	FDA	On	Actionable PGx			
PA166182752	Annotation of FDA Label for talazoparib and ERBB2	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166182941	Annotation of EMA Label for cobimetinib and BRAF	EMA		Testing required		Alternate Drug	Cancer Genome
PA166182943	Annotation of EMA Label for dolutegravir and UGT1A1	EMA		Actionable PGx			
PA166182944	Annotation of EMA Label for duloxetine and CYP2D6	EMA		Actionable PGx			
PA166183200	Annotation of EMA Label for midostaurin and FLT3	EMA		Testing required		Alternate Drug	Cancer Genome
PA166184231	Annotation of Swiss Label for umeclidinium and CYP2D6	Swiss		Informative PGx			
PA166104862	Annotation of FDA Label for desipramine and CYP2D6	FDA	On	Actionable PGx			
PA166104863	Annotation of FDA Label for dexlansoprazole and CYP2C19	FDA	On	Actionable PGx			
PA166104864	Annotation of FDA Label for paroxetine and CYP2D6	FDA	On	Informative PGx			
PA166104866	Annotation of FDA Label for pravastatin and APOE	FDA	Off (Formerly On)	Informative PGx			
PA166122947	Annotation of EMA Label for ranolazine and CYP2D6	EMA	Off (Never On)	Actionable PGx			
PA166104867	Annotation of FDA Label for telaprevir and IFNL3	FDA	On	Actionable PGx			
PA166104869	Annotation of FDA Label for galantamine and CYP2D6	FDA	On	Informative PGx			
PA166104868	Annotation of FDA Label for modafinil and CYP2D6	FDA	On	Actionable PGx			
PA166104870	Annotation of FDA Label for pimozide and CYP2D6	FDA	On	Testing required	Dosing Info		
PA166104877	Annotation of FDA Label for mycophenolic acid and HPRT1	FDA	On	Actionable PGx		Alternate Drug	
PA166104878	Annotation of FDA Label for methylene blue and G6PD	FDA	On	Actionable PGx		Alternate Drug	
PA166104879	Annotation of FDA Label for imipramine and CYP2D6	FDA	On	Actionable PGx			
PA166104880	Annotation of FDA Label for nefazodone and CYP2D6	FDA	On	Informative PGx			
PA166104881	Annotation of FDA Label for glibenclamide and G6PD	FDA	On	Actionable PGx			
PA166104882	Annotation of EMA Label for desloratadine	EMA	Off (Never On)	Informative PGx			
PA166104883	Annotation of FDA Label for denileukin diftitox and IL2RA	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104884	Annotation of FDA Label for clobazam and CYP2C19	FDA	On	Actionable PGx	Dosing Info		
PA166104885	Annotation of FDA Label for norfloxacin and G6PD	FDA	Off (Never On)	Actionable PGx			
PA166104886	Annotation of FDA Label for dextromethorphan / quinidine and CYP2D6	FDA	On	Testing recommended			
PA166104887	Annotation of FDA Label for iloperidone and CYP2D6	FDA	On	Actionable PGx	Dosing Info		
PA166104888	Annotation of FDA Label for nortriptyline and CYP2D6	FDA	On	Actionable PGx			
PA166104889	Annotation of FDA Label for pertuzumab and ERBB2	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104890	Annotation of FDA Label for ivacaftor and CFTR	FDA	On	Testing required		Alternate Drug	
PA166104898	Annotation of FDA Label for lansoprazole and CYP2C19	FDA	On	Informative PGx			
PA166104899	Annotation of EMA Label for aripiprazole and CYP2D6	EMA	Off (Never On)	Actionable PGx	Dosing Info		
PA166104900	Annotation of FDA Label for pegloticase and G6PD	FDA	On	Testing required		Alternate Drug	
PA166104901	Annotation of FDA Label for pantoprazole and CYP2C19	FDA	On	Actionable PGx			
PA166104902	Annotation of FDA Label for sulfadiazine and G6PD	FDA	On	Actionable PGx			
PA166104903	Annotation of FDA Label for nitrofurantoin and G6PD	FDA	On	Actionable PGx			
PA166104904	Annotation of EMA Label for brentuximab vedotin and TNFRSF8	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166104905	Annotation of EMA Label for capecitabine and DPYD	EMA	Off (Never On)	Testing recommended		Alternate Drug	
PA166104906	Annotation of FDA Label for probenecid and G6PD	FDA	On	Actionable PGx			
PA166104891	Annotation of FDA Label for nalidixic acid and G6PD	FDA	On	Actionable PGx			
PA166104892	Annotation of FDA Label for sulfasalazine and G6PD,NAT2	FDA	On	Actionable PGx			
PA166104893	Annotation of FDA Label for perphenazine and CYP2D6	FDA	On	Actionable PGx			
PA166104894	Annotation of EMA Label for rasburicase and G6PD	EMA	Off (Never On)	Actionable PGx		Alternate Drug	
PA166104895	Annotation of FDA Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD	FDA	On	Actionable PGx			
PA166104896	Annotation of EMA Label for abacavir and HLA-B	EMA	Off (Never On)	Testing required		Alternate Drug	
PA166104897	Annotation of FDA Label for moviprep and G6PD	FDA	On	Actionable PGx			
PA166104907	Annotation of EMA Label for eltrombopag and F5,SERPINC1	EMA	Off (Never On)	Actionable PGx			
PA166104908	Annotation of EMA Label for cetuximab and EGFR,KRAS,NRAS	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166104909	Annotation of EMA Label for crizotinib and ALK,ROS1	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166104911	Annotation of EMA Label for everolimus and ERBB2,ESR1,ESR2	EMA		Testing required		Alternate Drug	Cancer Genome
PA166104912	Annotation of FDA Label for eltrombopag and F5,SERPINC1	FDA	On	Actionable PGx			
PA166104913	Annotation of FDA Label for everolimus and ERBB2,ESR1,ESR2	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104914	Annotation of EMA Label for dasatinib and ABL1,BCR	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166104915	Annotation of EMA Label for olanzapine and CYP1A2,CYP2D6	EMA	Off (Never On)	Informative PGx			
PA166104916	Annotation of FDA Label for codeine and CYP2D6	FDA	On	Actionable PGx		Alternate Drug	
PA166104917	Annotation of FDA Label for prasugrel and CYP2B6,CYP2C19,CYP2C9,CYP3A5	FDA	On	Informative PGx			
PA166104919	Annotation of EMA Label for fulvestrant and ERBB2,ESR1,ESR2,PGR	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166104920	Annotation of FDA Label for trastuzumab and ERBB2	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104921	Annotation of FDA Label for omeprazole and CYP2C19	FDA	On	Actionable PGx			
PA166104922	Annotation of FDA Label for flurbiprofen and CYP2C9	FDA	On	Actionable PGx	Dosing Info		
PA166104923	Annotation of FDA Label for exemestane and ESR1,ESR2,PGR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166104924	Annotation of EMA Label for maraviroc and CCR5	EMA	Off (Never On)	Testing required		Alternate Drug	
PA166104926	Annotation of EMA Label for imatinib and ABL1,BCR,FIP1L1,KIT,PDGFRA,PDGFRB	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166104927	Annotation of EMA Label for lenalidomide	EMA	Off (Never On)	Informative PGx			
PA166104928	Annotation of EMA Label for ivacaftor and CFTR	EMA	Off (Never On)	Testing required		Alternate Drug	
PA166183246	Annotation of EMA Label for osimertinib and EGFR	EMA		Testing required		Alternate Drug	Cancer Genome
PA166177479	Annotation of FDA Label for cariprazine and CYP2D6	FDA	On	Informative PGx			
PA166177509	Annotation of FDA Label for formoterol and CYP2C19,CYP2D6	FDA	On	Informative PGx			
PA166177514	Annotation of FDA Label for mirabegron and CYP2D6	FDA	On	Actionable PGx			
PA166183421	Annotation of EMA Label for ribociclib and ERBB2,ESR1,ESR2,PGR	EMA		Testing required		Alternate Drug	Cancer Genome
PA166183441	Annotation of EMA Label for umeclidinium and CYP2D6	EMA		Informative PGx			
PA166183442	Annotation of EMA Label for vandetanib and RET	EMA		Testing recommended			Cancer Genome
PA166104930	Annotation of EMA Label for gefitinib and EGFR	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166122907	Annotation of EMA Label for vandetanib and RET	EMA	Off (Never On)	Testing recommended			
PA166152939	Annotation of FDA Label for ivacaftor / lumacaftor and CFTR	FDA	On	Testing required		Alternate Drug	
PA166159586	Annotation of HCSC Label for aliskiren and ABCB1	HCSC		Informative PGx			
PA166159964	Annotation of FDA Label for olaparib and BRCA1,BRCA2,ERBB2	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166160288	Annotation of HCSC Label for brentuximab vedotin and TNFRSF8	HCSC		Informative PGx			
PA166160668	Annotation of PMDA Label for allopurinol and HLA-B	PMDA		Actionable PGx			
PA166161536	Annotation of PMDA Label for atazanavir and CYP2C19	PMDA		Actionable PGx			
PA166160672	Annotation of FDA Label for tamsulosin and CYP2D6	FDA	On	Actionable PGx			
PA166160153	Annotation of PMDA Label for celecoxib and CYP2C9	PMDA	Off (Never On)	Actionable PGx			
PA166163431	Annotation of FDA Label for isosorbide mononitrate and CYB5R1,CYB5R2,CYB5R3,CYB5R4	FDA	On	Informative PGx			
PA166178750	Annotation of FDA Label for metoclopramide and CYP2D6	FDA	On	Actionable PGx	Dosing Info		
PA166179855	Annotation of FDA Label for avatrombopag and F2,F5,PROC,PROS1,SERPINC1	FDA	On	Actionable PGx			
PA166179878	Annotation of FDA Label for encorafenib and BRAF	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166182719	Annotation of FDA Label for ipilimumab and HLA-A	FDA	On	Informative PGx			
PA166182734	Annotation of FDA Label for larotrectinib sulfate and NTRK1,NTRK2,NTRK3	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166182737	Annotation of FDA Label for lidocaine and tetracaine and G6PD	FDA	On	Actionable PGx			
PA166182925	Annotation of EMA Label for amifampridine phosphate and NAT2	EMA		Actionable PGx			
PA166182929	Annotation of EMA Label for binimetinib and UGT1A1	EMA		Informative PGx			
PA166182947	Annotation of EMA Label for elosulfase alfa and GALNS	EMA		Testing required		Alternate Drug	
PA166182948	Annotation of EMA Label for encorafenib and BRAF	EMA		Testing required		Alternate Drug	Cancer Genome
PA166182952	Annotation of EMA Label for irinotecan and UGT1A1	EMA		Actionable PGx			
PA166183172	Annotation of EMA Label for lapatinib and HLA-DQA1,HLA-DRB1	EMA		Actionable PGx			
PA166183181	Annotation of EMA Label for lesinurad and CYP2C9	EMA		Actionable PGx			
PA166183209	Annotation of EMA Label for migalastat and GLA	EMA		Testing required		Alternate Drug	
PA166183220	Annotation of EMA Label for neratinib and ERBB2,ESR1,ESR2,PGR	EMA		Testing required		Alternate Drug	Cancer Genome
PA166183782	Annotation of Swiss Label for aspirin and G6PD	Swiss		Actionable PGx			
PA166183784	Annotation of Swiss Label for amifampridine phosphate and NAT2	Swiss		Actionable PGx			
PA166184232	Annotation of Swiss Label for venlafaxine and CYP2D6	Swiss		Actionable PGx			
PA166123543	Annotation of PMDA Label for indacaterol and UGT1A1	PMDA		Actionable PGx			
PA166122548	Annotation of EMA Label for velaglucerase alfa and GBA	EMA	Off (Never On)	Testing required		Alternate Drug	
PA166122971	Annotation of FDA Label for darifenacin and CYP2D6	FDA	On	Actionable PGx			
PA166105334	Annotation of EMA Label for nilotinib and ABL1,BCR	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166163417	Annotation of FDA Label for sofosbuvir / velpatasvir and IFNL3	FDA	On	Informative PGx			
PA166163433	Annotation of FDA Label for eteplirsen and DMD	FDA	On	Testing required		Alternate Drug	
PA166163419	Annotation of FDA Label for rucaparib and BRCA1,BRCA2	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166163420	Annotation of FDA Label for venetoclax and FLT3,IDH1,IDH2,NPM1,TP53	FDA	On	Informative PGx			Cancer Genome
PA166114317	Annotation of FDA Label for sodium phenylbutyrate and ASS1,CPS1,OTC	FDA	On	Testing required			
PA166105070	Annotation of FDA Label for anastrozole and ESR1,ESR2,PGR	FDA	On	Testing required			Cancer Genome
PA166105010	Annotation of FDA Label for duloxetine and CYP2D6	FDA	On	Actionable PGx			
PA166170048	Annotation of FDA Label for ribociclib and ERBB2,ESR1,ESR2,PGR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166170052	Annotation of FDA Label for valbenazine and CYP2D6	FDA	On	Actionable PGx			
PA166170933	Annotation of FDA Label for pertuzumab and ESR1,ESR2,PGR	FDA	On	Actionable PGx			Cancer Genome
PA166170936	Annotation of FDA Label for tamoxifen and F2,F5	FDA	On	Informative PGx			
PA166177483	Annotation of FDA Label for desvenlafaxine and CYP2D6	FDA	On	Informative PGx			
PA166177486	Annotation of FDA Label for enasidenib and IDH2	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166183249	Annotation of EMA Label for pembrolizumab and CD274	EMA		Testing required		Alternate Drug	Cancer Genome
PA166105315	Annotation of EMA Label for nelfinavir and CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166170932	Annotation of FDA Label for pembrolizumab and BRAF	FDA	On	Informative PGx			Cancer Genome
PA166179848	Annotation of FDA Label for lofexidine and CYP2D6	FDA	On	Actionable PGx			
PA166161219	Annotation of FDA Label for aripiprazole lauroxil and CYP2D6	FDA	On	Actionable PGx	Dosing Info	Alternate Drug	
PA166179847	Annotation of FDA Label for ivacaftor / tezacaftor and CFTR	FDA	On	Testing required		Alternate Drug	
PA166179870	Annotation of FDA Label for binimetinib and BRAF	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166179871	Annotation of FDA Label for binimetinib and UGT1A1	FDA	On	Informative PGx			
PA166182931	Annotation of EMA Label for brigatinib and ALK	EMA		Testing required		Alternate Drug	Cancer Genome
PA166159707	Annotation of HCSC Label for atazanavir and CYP2C19	HCSC		Informative PGx			
PA166153432	Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6	FDA	On	Actionable PGx			
PA166153492	Annotation of FDA Label for brivaracetam and CYP2C19	FDA	On	Actionable PGx			
PA166122487	Annotation of EMA Label for propranolol and CYP2D6	EMA	Off (Never On)	Informative PGx			
PA166182739	Annotation of FDA Label for tafenoquine and G6PD	FDA	On	Testing required		Alternate Drug	
PA166182762	Annotation of FDA Label for elagolix and SLCO1B1	FDA	On	Actionable PGx			
PA166105211	Annotation of FDA Label for ondansetron and CYP2D6	FDA	On	Informative PGx			
PA166105028	Annotation of FDA Label for nebivolol and CYP2D6	FDA	On	Informative PGx			
PA166182757	Annotation of FDA Label for inotersen and TTR	FDA	On	Informative PGx			
PA166182890	Annotation of FDA Label for olaparib and ESR1,ESR2,PGR	FDA	On	Informative PGx			Cancer Genome
PA166105012	Annotation of FDA Label for escitalopram and CYP2C19,CYP2D6	FDA	On	Actionable PGx			
PA166105113	Annotation of FDA Label for donepezil and CYP2D6	FDA	On	Actionable PGx			
PA166105319	Annotation of EMA Label for panitumumab and KRAS,NRAS	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166105321	Annotation of EMA Label for prasugrel and CYP2B6,CYP2C19,CYP2C9,CYP3A5	EMA	Off (Never On)	Informative PGx			
PA166105058	Annotation of FDA Label for pazopanib and HLA-B,UGT1A1	FDA	On	Actionable PGx			
PA166122589	Annotation of FDA Label for afutuzumab and MS4A1	FDA	On	Informative PGx			Cancer Genome
PA166122592	Annotation of FDA Label for simeprevir and IFNL3	FDA	On	Informative PGx			
PA166122970	Annotation of FDA Label for succinylcholine and BCHE,CACNA1S,RYR1	FDA	On	Actionable PGx		Alternate Drug	
PA166159064	Annotation of FDA Label for elosulfase alfa and GALNS	FDA	On	Testing required		Alternate Drug	
PA166159938	Annotation of HCSC Label for belimumab and TNFSF13B	HCSC		Informative PGx			
PA166159962	Annotation of FDA Label for alirocumab and LDLR	FDA	Off (Formerly On)	Informative PGx			
PA166160005	Annotation of FDA Label for dasabuvir / ombitasvir / paritaprevir / ritonavir and IFNL3	FDA	On	Informative PGx			
PA166160007	Annotation of FDA Label for lesinurad and CYP2C9	FDA	On	Actionable PGx			
PA166160009	Annotation of FDA Label for pembrolizumab and CD274	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166160046	Annotation of FDA Label for cobimetinib and BRAF	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166160054	Annotation of FDA Label for brexpiprazole and CYP2D6	FDA	On	Actionable PGx	Dosing Info		
PA166160056	Annotation of FDA Label for cholic acid and AKR1D1,AMACR,CYP27A1,CYP7A1,DHCR7,HSD3B7	FDA	Off (Formerly On)	Testing required		Alternate Drug	
PA166160121	Annotation of FDA Label for nivolumab and BRAF,CD274	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166122969	Annotation of EMA Label for vardenafil	EMA	Off (Never On)	Informative PGx			
PA166115435	Annotation of EMA Label for timolol and CYP2D6	EMA	Off (Never On)	Informative PGx			
PA166120286	Annotation of EMA Label for esomeprazole and CYP2C19	EMA	Off (Never On)	Informative PGx			
PA166114928	Annotation of FDA Label for mipomersen and LDLR	FDA	Off (Formerly On)	Informative PGx			
PA166105148	Annotation of FDA Label for glipizide and G6PD	FDA	On	Actionable PGx			
PA166114931	Annotation of FDA Label for ponatinib and ABL1,BCR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166105147	Annotation of FDA Label for glimepiride and G6PD	FDA	On	Actionable PGx			
PA166121326	Annotation of EMA Label for pazopanib and HLA-B	EMA	Off (Never On)	Actionable PGx			
PA166121252	Annotation of EMA Label for ofatumumab and MS4A1	EMA	Off (Never On)	Informative PGx			
PA166120287	Annotation of EMA Label for ethinyl estradiol / norelgestromin and F5,PROC,PROS1,SERPINC1	EMA	Off (Never On)	Actionable PGx		Alternate Drug	
PA166117941	Annotation of EMA Label for bosutinib and ABL1,BCR	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166122966	Annotation of EMA Label for darifenacin and CYP2D6	EMA	Off (Never On)	Actionable PGx			
PA166105059	Annotation of FDA Label for ofatumumab and MS4A1	FDA	Off (Formerly On)	Informative PGx			Cancer Genome
PA166121250	Annotation of EMA Label for lomitapide and APOB,LDLR,PCSK9	EMA	Off (Never On)	Testing required			
PA166114941	Annotation of FDA Label for pravastatin and LDLR	FDA	Off (Formerly On)	Informative PGx			
PA166121327	Annotation of EMA Label for pegloticase and G6PD	EMA	Off (Never On)	Testing required			
PA166114381	Annotation of EMA Label for sodium phenylbutyrate and ASS1,CPS1,OTC	EMA	Off (Never On)	Informative PGx		Alternate Drug	
PA166119824	Annotation of EMA Label for belimumab and TNFSF13B	EMA	Off (Never On)	Informative PGx			
PA166123542	Annotation of PMDA Label for imatinib and ABL1,BCR	PMDA		Testing required			
PA166114912	Annotation of FDA Label for dabrafenib and BRAF	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166121246	Annotation of EMA Label for ibritumomab and MS4A1	EMA	Off (Never On)	Informative PGx			
PA166114944	Annotation of FDA Label for regorafenib and EGFR,KRAS,VEGFA	FDA	Off (Formerly On)	Informative PGx			Cancer Genome
PA166105023	Annotation of FDA Label for rosuvastatin and SLCO1B1	FDA	On	Actionable PGx			
PA166119823	Annotation of EMA Label for afatinib and EGFR	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166120370	Annotation of EMA Label for glimepiride,pioglitazone and G6PD	EMA	Off (Never On)	Actionable PGx			
PA166121251	Annotation of EMA Label for mercaptopurine and NUDT15,TPMT	EMA	Off (Never On)	Actionable PGx			
PA166115362	Annotation of FDA Label for sodium nitrite and G6PD	FDA	On	Actionable PGx			
PA166122066	Annotation of EMA Label for pertuzumab and ERBB2	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166119827	Annotation of EMA Label for dextromethorphan / quinidine and CYP2D6	EMA	Off (Never On)	Actionable PGx			
PA166105232	Annotation of FDA Label for quinine and CYP2D6,G6PD	FDA	On	Actionable PGx		Alternate Drug	
PA166115363	Annotation of FDA Label for succimer and G6PD	FDA	On	Informative PGx			
PA166115365	Annotation of FDA Label for trametinib and BRAF	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166114905	Annotation of FDA Label for belimumab and TNFSF13B	FDA	Off (Formerly On)	Informative PGx			
PA166122546	Annotation of EMA Label for rituximab and MS4A1	EMA	Off (Never On)	Testing required			
PA166119826	Annotation of EMA Label for dabrafenib and BRAF	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166122547	Annotation of EMA Label for trastuzumab emtansine and ERBB2	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166123048	Annotation of EMA Label for cabazitaxel and CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166114481	Annotation of EMA Label for trastuzumab and ERBB2	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166114903	Annotation of FDA Label for afatinib and EGFR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166122067	Annotation of EMA Label for ponatinib and ABL1,BCR	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166114382	Annotation of EMA Label for ticagrelor and CYP2C19	EMA	Off (Never On)	Actionable PGx			
PA166122594	Annotation of FDA Label for sofosbuvir and IFNL3	FDA	On	Informative PGx			
PA166122607	Annotation of FDA Label for vortioxetine and CYP2D6	FDA	On	Actionable PGx			
PA166114482	Annotation of EMA Label for vemurafenib and BRAF	EMA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166114908	Annotation of FDA Label for carglumic acid and NAGS	FDA	On	Testing required		Alternate Drug	
PA166115367	Annotation of FDA Label for velaglucerase alfa and GBA	FDA	Off (Formerly On)	Testing required		Alternate Drug	
PA166114926	Annotation of FDA Label for mafenide and G6PD	FDA	On	Actionable PGx			
PA166114930	Annotation of FDA Label for homoharringtonine and ABL1,BCR	FDA	On	Informative PGx			Cancer Genome
PA166114907	Annotation of FDA Label for bosutinib and ABL1,BCR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166114921	Annotation of FDA Label for ibritumomab and MS4A1	FDA	Off (Formerly On)	Informative PGx			Cancer Genome
PA166114923	Annotation of FDA Label for lomitapide and LDLR	FDA	Off (Formerly On)	Informative PGx			
PA166169912	Annotation of FDA Label for enflurane and CACNA1S,RYR1	FDA	On	Actionable PGx		Alternate Drug	
PA166170957	Annotation of FDA Label for vemurafenib and HRAS,KRAS,NRAS	FDA	On	Informative PGx			Cancer Genome
PA166170958	Annotation of FDA Label for valproic acid and POLG	FDA	On	Testing required		Alternate Drug	
PA166122488	Annotation of EMA Label for regorafenib and KRAS	EMA	Off (Never On)	Actionable PGx			Cancer Genome
PA166114378	Annotation of EMA Label for telaprevir and IFNL3	EMA	Off (Never On)	Actionable PGx			
PA166114913	Annotation of FDA Label for dabrafenib and G6PD	FDA	On	Actionable PGx			
PA166182753	Annotation of FDA Label for meloxicam and CYP2C9	FDA	Off (Never On)	Actionable PGx			
PA166182759	Annotation of FDA Label for chloroprocaine and G6PD	FDA	On	Actionable PGx			
PA166182760	Annotation of FDA Label for docetaxel and ESR1,ESR2,PGR	FDA	On	Informative PGx			Cancer Genome
PA166182729	Annotation of FDA Label for amoxapine and CYP2D6	FDA	On	Actionable PGx			
PA166122967	Annotation of EMA Label for fesoterodine and CYP2D6	EMA	Off (Never On)	Actionable PGx			
PA166122826	Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166105195	Annotation of FDA Label for metoclopramide and CYB5R1,CYB5R2,CYB5R3,CYB5R4	FDA	On	Actionable PGx			
PA166105178	Annotation of FDA Label for lidocaine / prilocaine and G6PD	FDA	On	Actionable PGx			
PA166177475	Annotation of FDA Label for abemaciclib and ERBB2,ESR1,ESR2,PGR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166177512	Annotation of FDA Label for inotuzumab ozogamicin and ABL1,BCR	FDA	On	Informative PGx			Cancer Genome
PA166177516	Annotation of FDA Label for neratinib and ERBB2	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166177518	Annotation of FDA Label for sofosbuvir / velpatasvir / voxilaprevir and IFNL3	FDA	On	Informative PGx			
PA166183621	Annotation of Swiss Label for mefloquine and G6PD	Swiss		Informative PGx			
PA166183593	Annotation of Swiss Label for acenocoumarol and CYP2C9	Swiss		Actionable PGx			
PA166105222	Annotation of FDA Label for piroxicam and CYP2C9	FDA	On	Actionable PGx			
PA166105117	Annotation of FDA Label for efavirenz and CYP2B6	FDA	On	Actionable PGx			
PA166122968	Annotation of EMA Label for sildenafil	EMA	Off (Never On)	Informative PGx			
PA166122972	Annotation of FDA Label for fesoterodine and CYP2D6	FDA	On	Actionable PGx			
PA166114910	Annotation of FDA Label for chlorpropamide and G6PD	FDA	On	Actionable PGx			
PA166119825	Annotation of EMA Label for carglumic acid and NAGS	EMA	Off (Never On)	Testing required		Alternate Drug	
PA166105240	Annotation of FDA Label for rituximab and MS4A1	FDA	On	Informative PGx			Cancer Genome
PA166123423	Annotation of EMA Label for tipranavir and CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166123424	Annotation of EMA Label for darunavir and CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166123553	Annotation of PMDA Label for abacavir and HLA-B	PMDA	Off (Never On)	Informative PGx			
PA166123409	Annotation of EMA Label for aliskiren and ABCB1	EMA	Off (Never On)	Informative PGx			
PA166123416	Annotation of EMA Label for ivabradine and CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166123390	Annotation of EMA Label for fampridine and SLC22A2	EMA	Off (Never On)	Informative PGx			
PA166123418	Annotation of EMA Label for posaconazole and CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166123419	Annotation of EMA Label for indinavir and CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166123387	Annotation of EMA Label for axitinib and CYP2C19,UGT1A1	EMA	Off (Never On)	Informative PGx			
PA166123388	Annotation of EMA Label for ruxolitinib and CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166123420	Annotation of EMA Label for fosamprenavir and CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166123535	Annotation of PMDA Label for clopidogrel and CYP2C19	PMDA	Off (Never On)	Actionable PGx			
PA166123536	Annotation of PMDA Label for crizotinib and ALK	PMDA	Off (Never On)	Testing required			
PA166123412	Annotation of EMA Label for sunitinib and CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166123414	Annotation of EMA Label for dronedarone and CYP2D6,CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166123417	Annotation of EMA Label for telithromycin and CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166123527	Annotation of PMDA Label for arsenic trioxide and PML,RARA	PMDA	Off (Never On)	Testing required			
PA166123528	Annotation of PMDA Label for atomoxetine and CYP2D6	PMDA	Off (Never On)	Actionable PGx			
PA166123487	Annotation of FDA Label for eliglustat and CYP2D6	FDA	On	Testing required	Dosing Info		
PA166123537	Annotation of PMDA Label for dasatinib and ABL1,BCR	PMDA	Off (Never On)	Testing required			
PA166123408	Annotation of EMA Label for vortioxetine and CYP2D6	EMA	Off (Never On)	Actionable PGx	Dosing Info		
PA166123529	Annotation of PMDA Label for atorvastatin and LDLR	PMDA	Off (Never On)	Informative PGx			
PA166123530	Annotation of PMDA Label for azathioprine and TPMT	PMDA	Off (Never On)	Actionable PGx			
PA166163414	Annotation of FDA Label for ustekinumab and IL12A,IL12B,IL23A	FDA	On	Actionable PGx			
PA166163412	Annotation of FDA Label for ombitasvir / paritaprevir / ritonavir and IFNL3	FDA	On	Informative PGx			
PA166123538	Annotation of PMDA Label for eltrombopag and SERPINC1	PMDA		Actionable PGx			
PA166123539	Annotation of PMDA Label for fluorouracil and DPYD	PMDA		Actionable PGx			
PA166123421	Annotation of EMA Label for atazanavir and CYP2C19	EMA	Off (Never On)	Testing recommended			
PA166123531	Annotation of PMDA Label for capecitabine and DPYD	PMDA	Off (Never On)	Actionable PGx			
PA166123532	Annotation of PMDA Label for carbamazepine and HLA-A,HLA-B	PMDA	Off (Never On)	Actionable PGx			
PA166123540	Annotation of PMDA Label for fulvestrant and ESR1,ESR2	PMDA	Off (Never On)	Testing required			
PA166123541	Annotation of PMDA Label for gefitinib and CYP2D6,EGFR	PMDA		Testing required			
PA166123422	Annotation of EMA Label for efavirenz / emtricitabine / tenofovir disoproxil and CYP2B6	EMA	Off (Never On)	Actionable PGx			
PA166170929	Annotation of FDA Label for gefitinib and CYP2D6	FDA	On	Actionable PGx			
PA166170931	Annotation of FDA Label for midostaurin and KIT,NPM1	FDA	On	Informative PGx			
PA166169918	Annotation of FDA Label for midostaurin and FLT3	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166170934	Annotation of FDA Label for primaquine and CYB5R1,CYB5R2,CYB5R3,CYB5R4	FDA	On	Actionable PGx			
PA166170935	Annotation of FDA Label for rucaparib and CYP1A2,CYP2D6	FDA	On	Informative PGx			
PA166170937	Annotation of FDA Label for trametinib and G6PD	FDA	On	Informative PGx			
PA166170938	Annotation of FDA Label for trametinib and HRAS,KRAS,NRAS	FDA	On	Informative PGx			Cancer Genome
PA166182021	Annotation of FDA Label for amifampridine phosphate and NAT2	FDA	On	Actionable PGx	Dosing Info		
PA166182934	Annotation of EMA Label for cerliponase alfa and TPP1	EMA		Testing required		Alternate Drug	
PA166182725	Annotation of FDA Label for eribulin and ERBB2,ESR1,ESR2,PGR	FDA	On	Informative PGx			Cancer Genome
PA166182758	Annotation of FDA Label for goserelin and ESR1,ESR2,PGR	FDA	On	Informative PGx			
PA166182766	Annotation of FDA Label for fosphenytoin and HLA-B	FDA	On	Actionable PGx			
PA166182726	Annotation of FDA Label for rivaroxaban and F5	FDA	On	Informative PGx			
PA166182786	Annotation of FDA Label for tolazamide and G6PD	FDA	On	Actionable PGx			
PA166182787	Annotation of FDA Label for tolbutamide and G6PD	FDA	On	Actionable PGx			
PA166182750	Annotation of FDA Label for toremifene and ESR1,ESR2	FDA	On	Testing required			Cancer Genome
PA166182789	Annotation of EMA Label for toremifene and ESR1,ESR2	EMA		Actionable PGx			Cancer Genome
PA166182727	Annotation of FDA Label for ivosidenib and IDH1	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166182724	Annotation of FDA Label for ixabepilone and ERBB2,ESR1,ESR2,PGR	FDA	On	Informative PGx			Cancer Genome
PA166182744	Annotation of FDA Label for lorlatinib and ALK	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166182747	Annotation of FDA Label for lorlatinib and ROS1	FDA	On	Informative PGx			Cancer Genome
PA166182749	Annotation of FDA Label for lusutrombopag and F2,F5,PROC,PROS1,SERPINC1	FDA	On	Actionable PGx			
PA166182751	Annotation of FDA Label for mepivacaine and G6PD	FDA	On	Actionable PGx			
PA166182730	Annotation of FDA Label for amphetamine and CYP2D6	FDA	On	Informative PGx			
PA166182928	Annotation of EMA Label for binimetinib and BRAF	EMA		Testing required		Alternate Drug	Cancer Genome
PA166182932	Annotation of EMA Label for brivaracetam and CYP2C19	EMA		Actionable PGx			
PA166182942	Annotation of EMA Label for dacomitinib and EGFR	EMA		Testing required		Alternate Drug	Cancer Genome
PA166182953	Annotation of EMA Label for ivacaftor / lumacaftor and CFTR	EMA		Testing required		Alternate Drug	
PA166182954	Annotation of EMA Label for ivacaftor / tezacaftor and CFTR	EMA		Testing required		Alternate Drug	
PA166183247	Annotation of EMA Label for palbociclib and ERBB2,ESR1,ESR2,PGR	EMA		Testing required		Alternate Drug	Cancer Genome
PA166183248	Annotation of EMA Label for palonosetron and CYP2D6	EMA		Informative PGx			
PA166183251	Annotation of EMA Label for raltegravir and UGT1A1	EMA		Informative PGx			
PA166183425	Annotation of EMA Label for talazoparib and BRCA1,BRCA2,ERBB2	EMA		Testing required		Alternate Drug	Cancer Genome
PA166183783	Annotation of Swiss Label for allopurinol and HLA-B	Swiss		Actionable PGx			
PA166123410	Annotation of EMA Label for ritonavir and CYP2D6,CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166123411	Annotation of EMA Label for sirolimus and CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166123413	Annotation of EMA Label for zonisamide and CYP3A4	EMA	Off (Never On)	Informative PGx			
PA166169884	Annotation of FDA Label for durvalumab and CD274	FDA	On	Informative PGx			Cancer Genome
PA166127644	Annotation of HCSC Label for capecitabine and DPYD	HCSC		Actionable PGx			
PA166127645	Annotation of HCSC Label for carbamazepine and HLA-A,HLA-B	HCSC		Testing recommended			
PA166163421	Annotation of FDA Label for daclatasvir and IFNL3	FDA	On	Informative PGx			
PA166163422	Annotation of FDA Label for dronabinol and CYP2C9	FDA	On	Actionable PGx			
PA166127646	Annotation of HCSC Label for carvedilol and CYP2D6	HCSC		Actionable PGx			
PA166183424	Annotation of EMA Label for rucaparib and CYP1A2,CYP2D6	EMA		Informative PGx			
PA166127647	Annotation of HCSC Label for celecoxib and CYP2C9	HCSC		Actionable PGx			
PA166127648	Annotation of HCSC Label for cetuximab and EGFR,KRAS	HCSC		Testing required			
PA166127649	Annotation of HCSC Label for chlorpropamide and G6PD	HCSC		Actionable PGx			
PA166127650	Annotation of HCSC Label for citalopram and CYP2C19	HCSC		Actionable PGx			
PA166170930	Annotation of FDA Label for dabrafenib and HRAS,KRAS,NRAS	FDA	On	Informative PGx			
PA166170939	Annotation of FDA Label for trastuzumab and ESR1,ESR2,PGR	FDA	On	Actionable PGx			Cancer Genome
PA166182764	Annotation of FDA Label for emapalumab and PRF1,RAB27A,SH2D1A,STX11,STXBP2,UNC13D,XIAP	FDA	On	Informative PGx			
PA166160226	Annotation of PMDA Label for codeine and CYP2D6	PMDA		Actionable PGx			
PA166160683	Annotation of PMDA Label for dapsone and G6PD	PMDA		Actionable PGx			
PA166160162	Annotation of PMDA Label for efavirenz and CYP2B6	PMDA		Actionable PGx			
PA166160669	Annotation of PMDA Label for escitalopram and CYP2C19,CYP2D6	PMDA		Actionable PGx			
PA166160712	Annotation of PMDA Label for fesoterodine and CYP2D6	PMDA		Actionable PGx			
PA166160717	Annotation of PMDA Label for letrozole and CYP2A6	PMDA		Actionable PGx			
PA166160718	Annotation of PMDA Label for methylene blue and BLVRB,G6PD	PMDA		Actionable PGx			
PA166160719	Annotation of PMDA Label for nalidixic acid and G6PD	PMDA		Actionable PGx			
PA166160845	Annotation of PMDA Label for perphenazine and CYP2D6	PMDA		Actionable PGx			
PA166160846	Annotation of PMDA Label for rabeprazole and CYP2C19	PMDA		Actionable PGx			
PA166160847	Annotation of PMDA Label for sulfadiazine and G6PD	PMDA		Actionable PGx			
PA166160848	Annotation of PMDA Label for sulfamethoxazole / trimethoprim and G6PD	PMDA		Actionable PGx			
PA166160849	Annotation of PMDA Label for sulfasalazine and G6PD	PMDA		Actionable PGx			
PA166160850	Annotation of PMDA Label for tetrabenazine and CYP2D6	PMDA		Actionable PGx			
PA166160854	Annotation of PMDA Label for moviprep and G6PD	PMDA		Actionable PGx			
PA166160856	Annotation of PMDA Label for voriconazole and CYP2C19	PMDA		Actionable PGx			
PA166160274	Annotation of PMDA Label for cetuximab and EGFR,KRAS	PMDA		Testing required			
PA166160709	Annotation of PMDA Label for eliglustat and CYP2D6	PMDA		Testing required			
PA166160710	Annotation of PMDA Label for erlotinib and EGFR	PMDA		Testing required			
PA166160711	Annotation of PMDA Label for everolimus and ERBB2,ESR1,ESR2	PMDA		Testing required			
PA166160851	Annotation of PMDA Label for vemurafenib and BRAF	PMDA		Testing required			
PA166161087	Annotation of PMDA Label for isoniazid and NAT2	PMDA		Informative PGx			
PA166160720	Annotation of PMDA Label for omeprazole and CYP2C19	PMDA		Informative PGx			
PA166127702	Annotation of HCSC Label for primaquine and CYB5R1,CYB5R2,CYB5R3,CYB5R4,G6PD	HCSC		Actionable PGx			
PA166127704	Annotation of HCSC Label for propafenone and CYP2D6	HCSC		Actionable PGx			
PA166179887	Annotation of FDA Label for raltegravir and UGT1A1	FDA	On	Informative PGx			
PA166182768	Annotation of FDA Label for gilteritinib and FLT3	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166127705	Annotation of HCSC Label for quinine and G6PD	HCSC		Actionable PGx			
PA166127706	Annotation of HCSC Label for rabeprazole and CYP2C19	HCSC		Actionable PGx			
PA166127707	Annotation of HCSC Label for rasburicase and G6PD	HCSC		Testing recommended			
PA166127708	Annotation of HCSC Label for risperidone and CYP2D6	HCSC		Informative PGx			
PA166127709	Annotation of HCSC Label for rosuvastatin and LDLR	HCSC		Actionable PGx			
PA166163435	Annotation of FDA Label for olaratumab and PDGFRA	FDA	On	Informative PGx			Cancer Genome
PA166163439	Annotation of FDA Label for elbasvir / grazoprevir and IFNL3	FDA	On	Informative PGx			
PA166169920	Annotation of FDA Label for niraparib and BRCA1,BRCA2	FDA	On	Informative PGx			Cancer Genome
PA166182949	Annotation of EMA Label for erlotinib and UGT1A1	EMA		Actionable PGx			
PA166129517	Annotation of FDA Label for isoflurane and CACNA1S,RYR1	FDA	On	Actionable PGx		Alternate Drug	
PA166159584	Annotation of HCSC Label for afutuzumab and MS4A1	HCSC		Informative PGx			
PA166182769	Annotation of FDA Label for hydroxychloroquine and G6PD	FDA	On	Actionable PGx			
PA166182738	Annotation of FDA Label for siponimod and CYP2C9	FDA	Off (Never On)	Testing required	Dosing Info	Alternate Drug	
PA166182788	Annotation of HCSC Label for tolbutamide and G6PD	HCSC		Actionable PGx			
PA166129527	Annotation of HCSC Label for ponatinib and ABI1,BCR	HCSC		Testing required			
PA166183243	Annotation of EMA Label for olaparib and BRCA1,BRCA2,ERBB2	EMA		Testing required		Alternate Drug	Cancer Genome
PA166163428	Annotation of FDA Label for ledipasvir / sofosbuvir and IFNL3	FDA	On	Informative PGx			
PA166163429	Annotation of FDA Label for atezolizumab and CD274	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166163430	Annotation of FDA Label for isosorbide dinitrate and CYB5R1,CYB5R2,CYB5R3,CYB5R4	FDA	On	Informative PGx			
PA166180000	Annotation of FDA Label for meclizine and CYP2D6	FDA	On	Actionable PGx			
PA166182280	Annotation of FDA Label for dacomitinib and EGFR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166182940	Annotation of EMA Label for cholic acid and AKR1D1,AMACR,CYP27A1,CYP7A1,HSD3B7	EMA		Testing required		Alternate Drug	
PA166183219	Annotation of EMA Label for mirabegron and CYP2D6	EMA		Informative PGx			
PA166183590	Annotation of Swiss Label for maraviroc and CYP3A5	Swiss		Actionable PGx			
PA166183563	Annotation of Swiss Label for abacavir and HLA-B	Swiss		Testing required		Alternate Drug	
PA166151853	Annotation of FDA Label for nilotinib and UGT1A1	FDA	On	Actionable PGx			
PA166129525	Annotation of HCSC Label for carglumic acid and NAGS	HCSC		Testing required			
PA166129526	Annotation of HCSC Label for ceritinib and ALK	HCSC		Testing required			
PA166127699	Annotation of HCSC Label for panitumumab and EGFR,KRAS	HCSC		Testing required			
PA166181925	Annotation of FDA Label for tamoxifen and CYP2D6	FDA	Off (Never On)	Actionable PGx			
PA166127700	Annotation of HCSC Label for pertuzumab and ERBB2	HCSC		Testing required			
PA166127701	Annotation of HCSC Label for phenytoin and HLA-B	HCSC		Testing recommended			
PA166131627	Annotation of FDA Label for osimertinib and EGFR	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166182721	Annotation of FDA Label for erdafitinib and FGFR2,FGFR3	FDA	Off (Never On)	Testing required		Alternate Drug	Cancer Genome
PA166182722	Annotation of FDA Label for erdafitinib and CYP2C9	FDA	Off (Never On)	Actionable PGx			
PA166182886	Annotation of FDA Label for migalastat and GLA	FDA	On	Testing required		Alternate Drug	
PA166182961	Annotation of FDA Label for duvelisib	FDA	On	Informative PGx			Cancer Genome
PA166127632	Annotation of HCSC Label for arsenic trioxide and PML,RARA	HCSC		Testing required			
PA166127664	Annotation of FDA Label for ibrutinib	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166127633	Annotation of HCSC Label for atomoxetine and CYP2D6	HCSC		Actionable PGx			
PA166129553	Annotation of FDA Label for belinostat and UGT1A1	FDA	On	Actionable PGx	Dosing Info		
PA166127634	Annotation of HCSC Label for atorvastatin and LDLR	HCSC		Informative PGx			
PA166127635	Annotation of HCSC Label for azathioprine and TPMT	HCSC		Actionable PGx			
PA166127640	Annotation of HCSC Label for boceprevir and IFNL3	HCSC		Informative PGx			
PA166127641	Annotation of HCSC Label for bosutinib and ABL1,BCR	HCSC		Testing required			
PA166127660	Annotation of HCSC Label for dasatinib and ABI1,BCR	HCSC		Testing required			
PA166127661	Annotation of HCSC Label for dexlansoprazole and CYP2C19	HCSC		Actionable PGx			
PA166127717	Annotation of HCSC Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD	HCSC		Actionable PGx			
PA166127670	Annotation of HCSC Label for esomeprazole and CYP2C19	HCSC		Informative PGx			
PA166127672	Annotation of HCSC Label for exemestane and ESR1,ESR2	HCSC		Testing required			
PA166127673	Annotation of HCSC Label for fesoterodine and CYP2D6	HCSC		Actionable PGx			
PA166127674	Annotation of HCSC Label for fluorouracil and DPYD	HCSC		Actionable PGx			
PA166127682	Annotation of HCSC Label for imatinib and ABI1,BCR,FIP1L1,KIT,PDGFRA,PDGFRB	HCSC		Testing required			
PA166127665	Annotation of HCSC Label for divalproex sodium and POLG	HCSC		Testing required			
PA166127721	Annotation of HCSC Label for tolterodine and CYP2D6	HCSC		Informative PGx			
PA166127671	Annotation of HCSC Label for everolimus and ERBB2,ESR1,ESR2	HCSC		Testing required			
PA166127685	Annotation of HCSC Label for lapatinib and ERBB2,HLA-DQA1,HLA-DRB1	HCSC		Testing required			
PA166127675	Annotation of HCSC Label for galantamine and CYP2D6	HCSC		Informative PGx			
PA166127683	Annotation of HCSC Label for irinotecan and UGT1A1	HCSC		Actionable PGx			
PA166127722	Annotation of HCSC Label for trametinib and BRAF	HCSC		Testing required			
PA166127724	Annotation of HCSC Label for trastuzumab and ERBB2	HCSC		Testing required			
PA166127686	Annotation of HCSC Label for lenalidomide	HCSC		Informative PGx			
PA166127687	Annotation of HCSC Label for letrozole and ESR1,ESR2,PGR	HCSC		Testing required			
PA166127688	Annotation of HCSC Label for lomitapide and LDLR	HCSC		Informative PGx			
PA166127693	Annotation of HCSC Label for nilotinib and ABI1,BCR	HCSC		Testing required			
PA166127694	Annotation of HCSC Label for nitrofurantoin and G6PD	HCSC		Actionable PGx			
PA166127684	Annotation of HCSC Label for ivacaftor and CFTR	HCSC		Testing required			
PA166151882	Annotation of FDA Label for carbamazepine and HLA-A	FDA	On	Actionable PGx			
PA166160021	Annotation of FDA Label for cabozantinib and RET	FDA	On	Informative PGx			
PA166182923	Annotation of EMA Label for abemaciclib and ERBB2,ESR1,ESR2,PGR	EMA		Testing required		Alternate Drug	Cancer Genome
PA166182924	Annotation of EMA Label for alectinib and ALK	EMA		Testing required		Alternate Drug	Cancer Genome
PA166182926	Annotation of EMA Label for atezolizumab and CD274	EMA		Testing required			Cancer Genome
PA166182930	Annotation of EMA Label for brexpiprazole and CYP2D6	EMA		Actionable PGx	Dosing Info		
PA166182945	Annotation of EMA Label for efavirenz and CYP2B6	EMA		Actionable PGx			
PA166182950	Annotation of EMA Label for gefitinib and CYP2D6	EMA		Actionable PGx			
PA166182951	Annotation of EMA Label for glibenclamide and G6PD	EMA		Actionable PGx		Alternate Drug	
PA166183171	Annotation of EMA Label for lacosamide and CYP2C19	EMA		Informative PGx			
PA166127723	Annotation of HCSC Label for trastuzumab emtansine and ERBB2	HCSC		Testing required			
PA166127725	Annotation of HCSC Label for tretinoin and PML,RARA	HCSC		Testing required			
PA166127689	Annotation of HCSC Label for maraviroc and CCR5	HCSC		Testing required			
PA166127695	Annotation of HCSC Label for ethinyl estradiol / norelgestromin and F2,F5,MTHFR,PROC,PROS1,SERPINC1	HCSC		Actionable PGx			
PA166127696	Annotation of HCSC Label for norfloxacin and G6PD	HCSC		Actionable PGx			
PA166129519	Annotation of FDA Label for sevoflurane and CACNA1S,RYR1	FDA	On	Actionable PGx		Alternate Drug	
PA166183183	Annotation of EMA Label for lidocaine / prilocaine and G6PD	EMA		Actionable PGx			
PA166127726	Annotation of HCSC Label for valproic acid and OTC,POLG	HCSC		Actionable PGx			
PA166127727	Annotation of HCSC Label for velaglucerase alfa and GBA	HCSC		Testing required			
PA166127690	Annotation of HCSC Label for mercaptopurine and TPMT	HCSC		Actionable PGx			
PA166127697	Annotation of HCSC Label for nortriptyline and CYP2D6	HCSC		Actionable PGx			
PA166127698	Annotation of HCSC Label for omeprazole and CYP2C19	HCSC		Informative PGx			
PA166129520	Annotation of HCSC Label for sevoflurane and CACNA1S,RYR1	HCSC	Off (Never On)	Actionable PGx			
PA166127728	Annotation of HCSC Label for vemurafenib and BRAF	HCSC		Testing required			
PA166127729	Annotation of HCSC Label for moviprep and G6PD	HCSC		Actionable PGx			
PA166160061	Annotation of FDA Label for dinutuximab and MYCN	FDA	On	Informative PGx			Cancer Genome
PA166182741	Annotation of FDA Label for articaine / epinephrine and G6PD	FDA	On	Actionable PGx			
PA166182746	Annotation of FDA Label for ceftriaxone and G6PD	FDA	On	Actionable PGx			
PA166183423	Annotation of EMA Label for rucaparib and BRCA1,BRCA2	EMA		Testing required		Alternate Drug	Cancer Genome
PA166123526	Annotation of PMDA Label for irinotecan and UGT1A1	PMDA		Testing recommended			
PA166123544	Annotation of PMDA Label for lapatinib and ERBB2,HLA-DQA1,HLA-DRB1	PMDA		Testing required			
PA166127719	Annotation of HCSC Label for tetrabenazine and CYP2D6	HCSC		Actionable PGx			
PA166127720	Annotation of HCSC Label for thioguanine and TPMT	HCSC		Actionable PGx			
PA166123545	Annotation of PMDA Label for lenalidomide	PMDA		Informative PGx			
PA166123546	Annotation of PMDA Label for mycophenolic acid and HPRT1	PMDA		Actionable PGx			
PA166129447	Annotation of EMA Label for eliglustat and CYP2D6	EMA		Testing required	Dosing Info	Alternate Drug	
PA166129450	Annotation of EMA Label for trametinib and BRAF	EMA		Testing required		Alternate Drug	Cancer Genome
PA166123547	Annotation of PMDA Label for panitumumab and KRAS	PMDA		Testing required			
PA166123548	Annotation of PMDA Label for rasburicase and G6PD	PMDA		Actionable PGx			
PA166129518	Annotation of HCSC Label for isoflurane and CACNA1S,RYR1	HCSC	Off (Never On)	Actionable PGx			
PA166127710	Annotation of HCSC Label for simeprevir and IFNL3	HCSC		Informative PGx			
PA166127712	Annotation of HCSC Label for sodium phenylbutyrate and ASS1,CPS1,OTC	HCSC		Testing required			
PA166129448	Annotation of EMA Label for ibrutinib	EMA		Testing required			Cancer Genome
PA166123549	Annotation of PMDA Label for tolterodine and CYP2D6	PMDA		Informative PGx			
PA166123550	Annotation of PMDA Label for trastuzumab and ERBB2	PMDA	Off (Never On)	Testing required			
PA166129528	Annotation of HCSC Label for sodium nitrite and G6PD	HCSC		Actionable PGx			
PA166127713	Annotation of HCSC Label for succinylcholine and BCHE	HCSC		Actionable PGx			
PA166123551	Annotation of PMDA Label for tretinoin and PML,RARA	PMDA		Informative PGx			
PA166123552	Annotation of PMDA Label for valproic acid and CPS1,OTC	PMDA	Off (Never On)	Actionable PGx			
PA166127714	Annotation of HCSC Label for sulfadiazine and G6PD	HCSC		Actionable PGx			
PA166127715	Annotation of HCSC Label for sulfamethoxazole / trimethoprim and G6PD	HCSC		Actionable PGx			
PA166177521	Annotation of FDA Label for umeclidinium and CYP2D6	FDA	On	Informative PGx			
PA166104776	Annotation of FDA Label for warfarin and CYP2C9,PROC,PROS1,VKORC1	FDA	On	Actionable PGx			
PA166127730	Annotation of HCSC Label for voriconazole and CYP2C19	HCSC		Actionable PGx			
PA166127731	Annotation of HCSC Label for vortioxetine and CYP2D6	HCSC		Actionable PGx			
PA166127716	Annotation of HCSC Label for sulfasalazine and G6PD	HCSC		Actionable PGx			
PA166124617	Annotation of FDA Label for ceritinib and ALK	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166127662	Annotation of FDA Label for arformoterol and CYP2D6,UGT1A1	FDA	On	Informative PGx			
PA166127732	Annotation of HCSC Label for warfarin and CYP2C9,VKORC1	HCSC		Actionable PGx			
PA166127718	Annotation of HCSC Label for tamoxifen and CYP2D6,ESR1,ESR2	HCSC		Testing required			
PA166129449	Annotation of EMA Label for ceritinib and ALK	EMA		Testing required		Alternate Drug	Cancer Genome
PA166129515	Annotation of FDA Label for desflurane and CACNA1S,RYR1	FDA	On	Actionable PGx		Alternate Drug	
PA166127691	Annotation of HCSC Label for metoprolol and CYP2D6	HCSC		Actionable PGx			
PA166127692	Annotation of HCSC Label for mycophenolic acid and HPRT1	HCSC		Actionable PGx			
PA166127655	Annotation of HCSC Label for crizotinib and ALK	HCSC		Testing required			
PA166127656	Annotation of HCSC Label for dabrafenib and BRAF	HCSC		Testing required			
PA166129516	Annotation of HCSC Label for desflurane and CACNA1S,RYR1	HCSC	Off (Never On)	Actionable PGx			
PA166127627	Annotation of HCSC Label for abacavir and HLA-B	HCSC		Testing required			
PA166127628	Annotation of HCSC Label for acetaminophen,tramadol and CYP2D6	HCSC		Actionable PGx			
PA166169877	Annotation of FDA Label for avelumab and CD274	FDA	On	Informative PGx			
PA166169878	Annotation of FDA Label for brigatinib and ALK	FDA	On	Testing required		Alternate Drug	Cancer Genome
PA166169880	Annotation of FDA Label for cerliponase alfa and TPP1	FDA	On	Testing required		Alternate Drug	
PA166182765	Annotation of FDA Label for flutamide and G6PD	FDA	On	Actionable PGx			
PA166151881	Annotation of FDA Label for rasburicase and G6PD	FDA	On	Testing required		Alternate Drug	
PA166127653	Annotation of HCSC Label for clopidogrel and CYP2C19	HCSC		Actionable PGx			
PA166127666	Annotation of HCSC Label for drospirenone / ethinyl estradiol and F5,PROC,PROS1,SERPINC1	HCSC		Actionable PGx			
PA166127667	Annotation of HCSC Label for efavirenz / emtricitabine / tenofovir disoproxil and CYP2B6	HCSC		Actionable PGx			
PA166127629	Annotation of HCSC Label for afatinib and EGFR	HCSC	On	Testing required			Cancer Genome
PA166127630	Annotation of HCSC Label for anastrozole and ESR1,ESR2,PGR	HCSC		Testing required			
PA166127676	Annotation of HCSC Label for gefitinib and EGFR	HCSC		Testing required			
PA166127677	Annotation of HCSC Label for glibenclamide and G6PD	HCSC		Actionable PGx			
PA166127654	Annotation of HCSC Label for codeine and CYP2D6	HCSC		Actionable PGx			
PA166127668	Annotation of HCSC Label for eltrombopag and F5,SERPINC1	HCSC		Actionable PGx			
PA166127669	Annotation of HCSC Label for erlotinib and EGFR	HCSC		Testing required			
PA166127663	Annotation of FDA Label for divalproex sodium and POLG	FDA	Off (Formerly On)	Testing required		Alternate Drug	
PA166127631	Annotation of HCSC Label for aripiprazole and CYP2D6	HCSC		Actionable PGx			
PA166127678	Annotation of HCSC Label for glimepiride and G6PD	HCSC		Actionable PGx			
PA166127681	Annotation of HCSC Label for ibrutinib	HCSC		Testing required			
PA166127657	Annotation of HCSC Label for dapsone and G6PD	HCSC		Actionable PGx			
PA166127659	Annotation of HCSC Label for darifenacin and CYP2D6	HCSC		Actionable PGx			
